Aprea Therapeutics Raises Approx. €5M in Series C Funding
Summary
Aprea Therapeutics , a Boston, Massachusetts- and Stockholm, Sweden-based clinical-stage biotechnology company developing novel anticancer therapies targeting the p53 tumor suppressor protein, raised approx. Funds managed by Janus Henderson Investors joined as a new backer, raising the total amount of the financing to €55m. Janus Henderson Investors joined the financing round closed in November, 2018 , and led by Redmile Group, with participation from Rock Springs Capital and existing investors 5AM Ventures, Versant Ventures, HealthCap, Sectoral Asset Management and Karolinska Development AB (Nasdaq Stockholm: KDEV). Led by Christian S. Schade, President and Chief Executive Officer, Aprea Therapeutics is a biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company’s lead drug candidate, APR-246, a first-in-class small molecule, is in clinical development for myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies.